3.06

0.66% 0.02

After Hours: 3.07 0.010 +0.33%

Altimmune Inc (ALT)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split Dividend History

Altimmune Inc stock is traded at $3.06, with a volume of 2.86M. It is up +0.66% in the last 24 hours and down -4.38% over the past month. Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Previous Close:

$3.04

Open:

$3.05

24h Volume:

2.86M

Relative Volume:

0.65

Market Cap:

$595.22M

Revenue:

$36,000

Net Income/Loss:

$-91.08M

P/E Ratio:

-3.2637

EPS:

-0.9376

Net Cash Flow:

$-71.67M

1W Performance:

-5.85%

1M Performance:

-4.38%

6M Performance:

-7.55%

1Y Performance:

-21.94%

1-Day Range:

$3.00

$3.11

1-Week Range:

$2.98

$3.425

52-Week Range:

$2.56

$6.4399

Altimmune Inc Stock (ALT) Company Profile

Name

Altimmune Inc

Sector

Healthcare (1067)

Industry

Biotechnology (595)

Phone

(240) 654-1450

Address

910 CLOPPER ROAD, GAITHERSBURG, MD

Employee

Twitter

Next Earnings Date

2026-11-05

Latest SEC Filings

ALT's Discussions on Twitter

Compare ALT vs VRTX, REGN, MRNA, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ALT Altimmune Inc	3.06	595.22M	36,000	-91.08M	-71.67M	-0.9376
VRTX Vertex Pharmaceuticals Inc	526.19	133.37B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	788.04	81.13B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	198.88	79.40B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	959.49	60.03B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	204.97	43.93B	742.00K	-1.37B	-1.07B	-7.0731

Altimmune Inc Stock (ALT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-24-26	Upgrade	Goldman	Sell → Neutral
Mar-18-26	Initiated	Truist	Buy
Jan-28-26	Initiated	Barclays	Overweight
Jul-10-25	Resumed	Goldman	Sell
Feb-28-25	Initiated	William Blair	Mkt Perform
Jan-08-25	Initiated	Stifel	Buy
Nov-12-24	Initiated	UBS	Buy
Apr-29-24	Downgrade	Guggenheim	Buy → Neutral
Jan-24-24	Initiated	Goldman	Neutral
Mar-22-23	Downgrade	Goldman	Buy → Neutral
Dec-01-22	Initiated	Goldman	Buy
Dec-29-21	Resumed	Jefferies	Buy
Jun-02-21	Initiated	H.C. Wainwright	Buy
Feb-11-21	Initiated	Guggenheim	Buy
Dec-14-20	Initiated	Jefferies	Buy
Nov-12-20	Reiterated	B. Riley Securities	Buy
Sep-25-20	Initiated	B. Riley FBR	Buy
Aug-14-20	Initiated	Evercore ISI	Outperform
Jul-31-20	Initiated	Piper Sandler	Overweight
Jul-28-20	Initiated	JMP Securities	Mkt Outperform
Feb-24-20	Resumed	ROTH Capital	Buy
Jul-19-19	Initiated	ROTH Capital	Buy
Oct-09-17	Initiated	Piper Jaffray	Overweight

View All

Altimmune Inc Stock (ALT) Latest News

Sep 25, 2026

Altimmune Stock Price Forecast. Should You Buy ALT? - StockInvest.us

Sep 25, 2026

ALT Stock Reverses Early Gains On Positive Alcohol Use Trial — But Wall Street, Retail Investors Dismiss Selloff - Stocktwits

Sep 25, 2026

Sep 24, 2026

ALT Stock Has Nearly Halved In The Past Year, So Why Does Wall Street See Almost 500% Upside? - Stocktwits

Sep 24, 2026

symbol__ Stock Quote Price and Forecast - CNN

Sep 24, 2026

Sep 23, 2026

Evercore Maintains Altimmune(ALT.US) With Buy Rating, Cuts Target Price to $17 - Moomoo

Sep 23, 2026

Altimmune’s Phase 3 MASH Trial Puts Pemvidutide in the Spotlight for Investors - TipRanks

Sep 23, 2026

ALT Maintained by Evercore ISI Group -- Price Target Lowered to $17 - GuruFocus

Sep 23, 2026

Altimmune to Participate in Stifel Cardiometabolic Forum - The Manila Times

Sep 23, 2026